Northside Capital Management LLC Continues to Hold Position in Amgen Inc. (AMGN)
Northside Capital Management LLC continued to hold its position in Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,871 shares of the medical research company’s stock at the end of the second quarter. Northside Capital Management LLC’s holdings in Amgen were worth $437,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Oakworth Capital Inc. raised its position in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares during the period. Delta Asset Management LLC TN raised its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares during the last quarter. Capital Advisors Ltd. LLC raised its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares during the last quarter. Vigilant Capital Management LLC raised its stake in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares during the last quarter. Finally, Calamos Wealth Management LLC acquired a new stake in shares of Amgen during the second quarter worth $202,000. Institutional investors own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded down 2.37% during mid-day trading on Tuesday, reaching $164.32. The company’s stock had a trading volume of 2,761,288 shares. The company’s 50-day moving average is $170.60 and its 200 day moving average is $162.14. The firm has a market capitalization of $122.97 billion, a P/E ratio of 16.82 and a beta of 0.94. Amgen Inc. has a 1-year low of $139.02 and a 1-year high of $176.85.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.74 by $0.10. The business earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period last year, the firm earned $2.57 EPS. On average, analysts expect that Amgen Inc. will post $11.35 earnings per share for the current year.
A number of brokerages have recently weighed in on AMGN. Vetr lowered Amgen from a “strong-buy” rating to a “buy” rating and set a $185.76 price target on the stock. in a research note on Tuesday, October 4th. Jefferies Group restated a “buy” rating on shares of Amgen in a research note on Wednesday, September 28th. Citigroup Inc. dropped their price target on Amgen from $175.00 to $172.00 and set a “neutral” rating on the stock in a research note on Wednesday, September 28th. JPMorgan Chase & Co. restated a “hold” rating on shares of Amgen in a research note on Wednesday, September 28th. Finally, Goldman Sachs Group Inc. restated a “buy” rating and set a $206.00 price target (up previously from $204.00) on shares of Amgen in a research note on Tuesday, September 27th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $184.94.
In other news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.